Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The latest update is out from EQL Pharma AB ( (SE:EQL) ).
EQL Pharma AB, a Lund-based specialist in niche generic prescription medicines for Nordic and European markets, continues to build out a significant pipeline beyond its 47 already launched products. The company leverages partnerships with major EU and Asian pharmaceutical manufacturers and is listed on Nasdaq Stockholm, underscoring its role in the regional generics ecosystem.
The company will publish its year-end report for the fourth quarter of fiscal 2025/26 on May 8, 2026, followed by a video conference presentation for current and prospective shareholders. CEO and President Axel Schörling will present and comment on the results, with an opportunity for participants to ask questions, signaling EQL Pharma’s ongoing emphasis on investor communication and transparency around its financial performance and strategic progress.
More about EQL Pharma AB
EQL Pharma AB is a Sweden-based pharmaceutical company focused on developing and selling generic prescription drugs, particularly niche generics with limited competition against original products. The company has 47 such generics launched across Nordic markets and is expanding its pipeline for 2026 and beyond, targeting both retail and hospital segments in the Nordics and wider Europe. EQL collaborates with leading contract manufacturers and major pharma partners in the EU and Asia, and its shares are listed on Nasdaq Stockholm, with operations headquartered in Lund.
Average Trading Volume: 28,173
Technical Sentiment Signal: Hold
Current Market Cap: SEK1.61B
Find detailed analytics on EQL stock on TipRanks’ Stock Analysis page.